

Annexin Q4 2023 - Continued RVO progress

Redeye returns with an update following Annexin's Q4 report, and the company continued to present advancements from its ongoing phase II study. We slightly raise our base case.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Annexin Q4 2023 - Continued RVO progress